Cargando…

Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance

The interferon (IFN)-mediated activation of the Janus kinase (JAK)-signal transducer and activator of transcription 1 (STAT1) signaling is crucial for cell sensitivity to ionizing radiation. Several preclinical studies have reported that the IFN/STAT1 pathway mediates radioresistance in the tumor mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shuya, Imani, Saber, Deng, Youcai, Pathak, Janak L, Wen, Qinglian, Chen, Yue, Wu, Jingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321691/
https://www.ncbi.nlm.nih.gov/pubmed/32606809
http://dx.doi.org/10.2147/OTT.S256708
_version_ 1783551526795476992
author Liu, Shuya
Imani, Saber
Deng, Youcai
Pathak, Janak L
Wen, Qinglian
Chen, Yue
Wu, Jingbo
author_facet Liu, Shuya
Imani, Saber
Deng, Youcai
Pathak, Janak L
Wen, Qinglian
Chen, Yue
Wu, Jingbo
author_sort Liu, Shuya
collection PubMed
description The interferon (IFN)-mediated activation of the Janus kinase (JAK)-signal transducer and activator of transcription 1 (STAT1) signaling is crucial for cell sensitivity to ionizing radiation. Several preclinical studies have reported that the IFN/STAT1 pathway mediates radioresistance in the tumor microenvironment by shielding the immune responses and activating survival signaling pathways. This review focuses on the oncogenic function of the IFN/STAT1 pathway, emphasizing the major signaling pathway in radiation sensitization. Furthermore, it highlights the possibility of mediatory roles of the IFN/STAT1 pathway as a prognostic therapeutic target in the modulation of resistance to radiotherapy and chemotherapy. MicroRNA involved in the regulation of the IFN/STAT1 pathway is also discussed. A better understanding of radiation-induced IFN/STAT1 signaling will open new opportunities for the development of novel therapeutic strategies, as well as define new approaches to enhance radio-immunotherapy efficacy in the treatment of various types of cancers.
format Online
Article
Text
id pubmed-7321691
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73216912020-06-29 Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance Liu, Shuya Imani, Saber Deng, Youcai Pathak, Janak L Wen, Qinglian Chen, Yue Wu, Jingbo Onco Targets Ther Review The interferon (IFN)-mediated activation of the Janus kinase (JAK)-signal transducer and activator of transcription 1 (STAT1) signaling is crucial for cell sensitivity to ionizing radiation. Several preclinical studies have reported that the IFN/STAT1 pathway mediates radioresistance in the tumor microenvironment by shielding the immune responses and activating survival signaling pathways. This review focuses on the oncogenic function of the IFN/STAT1 pathway, emphasizing the major signaling pathway in radiation sensitization. Furthermore, it highlights the possibility of mediatory roles of the IFN/STAT1 pathway as a prognostic therapeutic target in the modulation of resistance to radiotherapy and chemotherapy. MicroRNA involved in the regulation of the IFN/STAT1 pathway is also discussed. A better understanding of radiation-induced IFN/STAT1 signaling will open new opportunities for the development of novel therapeutic strategies, as well as define new approaches to enhance radio-immunotherapy efficacy in the treatment of various types of cancers. Dove 2020-06-24 /pmc/articles/PMC7321691/ /pubmed/32606809 http://dx.doi.org/10.2147/OTT.S256708 Text en © 2020 Liu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Liu, Shuya
Imani, Saber
Deng, Youcai
Pathak, Janak L
Wen, Qinglian
Chen, Yue
Wu, Jingbo
Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance
title Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance
title_full Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance
title_fullStr Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance
title_full_unstemmed Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance
title_short Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance
title_sort targeting ifn/stat1 pathway as a promising strategy to overcome radioresistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321691/
https://www.ncbi.nlm.nih.gov/pubmed/32606809
http://dx.doi.org/10.2147/OTT.S256708
work_keys_str_mv AT liushuya targetingifnstat1pathwayasapromisingstrategytoovercomeradioresistance
AT imanisaber targetingifnstat1pathwayasapromisingstrategytoovercomeradioresistance
AT dengyoucai targetingifnstat1pathwayasapromisingstrategytoovercomeradioresistance
AT pathakjanakl targetingifnstat1pathwayasapromisingstrategytoovercomeradioresistance
AT wenqinglian targetingifnstat1pathwayasapromisingstrategytoovercomeradioresistance
AT chenyue targetingifnstat1pathwayasapromisingstrategytoovercomeradioresistance
AT wujingbo targetingifnstat1pathwayasapromisingstrategytoovercomeradioresistance